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Abstract

REVERSAL OF THE NPC PHENOTYPE BY START DOMAIN PROTEINS
By Tavis H. Sparrer, M.S.
A Thesis submitted in partial fulfillment of requirements for the degree of a Master of Science
degree at Virginia Commonwealth University.
Virginia Commonwealth University, 2017.
Major Director: Dr. Gregorio Gil, Professor, Department of Biochemistry and Molecular Biology

Niemann Pick Type C (NPC) disease is a fatal childhood neurological disease caused by
mutations in the NPC-1 protein, resulting in cholesterol buildup in the late endosomes. StarD4
and StarD5 are cholesterol binding proteins that play a role in the intracellular cholesterol
transport. In this study we overexpress StarD4 and StarD5 in in vitro and in vivo models, and
find evidence of amelioration of the NPC phenotype. This study demonstrates that the
overexpression of these proteins has the potential to be a therapeutic treatment for NPC disease.

Introduction & Background

Cholesterol and Atherosclerosis
Cholesterol is a sterol that plays an important role in mammal biology. It is an integral
component of cellular membranes in mammals, and is responsible for maintaining membrane
fluidity and integrity by intercalating itself between phospholipid molecules. Cholesterol is
therefore needed for the synthesis of additional cellular membranes, and is necessary for cellular
division. Cholesterol can be stored in lipid droplets as esterified cholesterol (EC) or can exist in
cellular membranes as free cholesterol (FC). The plasma membrane of the cell has the highest
concentration of free cholesterol, with 0.128 mg of cholesterol per mg of protein. Membranes of
organelles have less- the Golgi body, endoplasmic reticulum, and mitochondria have 0.071,
0.014, and 0.003 mg/mg protein respectively [1]. Cholesterol is also converted into steroid
hormones such as corticosteroids in the adrenal glands.
Cholesterol can be taken in through the diet or synthesized from acetyl-CoA in the
endoplasmic reticulum (ER). This pathway includes the rate limiting step of cholesterol
synthesis- the production of mevalonic acid from 3-hydroxy-3methylgutaryl-CoA (HMG-CoA)
by HMG-CoA reductase [2]. Synthesis of cholesterol is particularly important in the brain,
which is completely reliant on endogenous cholesterol produced in astrocytes. While diets in
western countries tend to be high in cholesterol, the body has limited options of eliminating it.
Cholesterol is transported through the bloodstream via lipoproteins. These phospholipid
monolayers enclose a hydrophobic compartment that is used to transport lipids through the
blood. Embedded in this monolayer are apolipoproteins, which are used to interact with plasma
membrane receptors. High Density Lipoprotein (HDL), which is synthesized in the liver, is
1

responsible for transport of cholesterol from the periphery and macrophages to the liver [3].
Transport into the liver is the primary mechanism of eliminating cholesterol from the body. In
the liver, cholesterol is excreted into the bile or converted into bile acids [4]. Low Density
Lipoprotein (LDL) is formed from Very Low Density Lipoprotein (VLDL), a lipoprotein
synthesized by the liver mainly from endogenous lipids. LDL can be taken up by the liver,
peripheral tissues or by macrophages by binding with the LDL receptor. LDL binding to LDL
receptor allows it to be internalized by the cell by clatherin mediated endocytosis. LDL is then
taken into lysosomes and cholesterol esters are hydrolyzed into free cholesterol.
SREBP-2 (Sterol Regulatory Element Binding Protein 2) is a transcription factor that
upregulates genes involved in cholesterol synthesis and uptake [5]. SREBP-2 exists in an
inactive form in the ER. In the absence of cholesterol or fatty acids, SREBP cleavage activating
protein (SCAP) escorts SREBP-2 to the Golgi where it is cleaved, activated, and translocated to
the nucleus. There, SREBP-2 activates the transcription of genes involved in cholesterol
synthesis and uptake, such as HMG-CoA reductase and LDL receptor [6]. SREBP-1 is another
sterol regulatory element binding protein, and has a mechanism of action is similar to SREBP-2.
SREBP-1 is present in the ER and is cleaved in the absence of fatty acids and sterols [7].
Cleavage triggers transport to the Golgi and subsequent translocation to the nucleus where it
activates the transcription of genes involved in fatty acid and lipid synthesis, such as Acetyl-CoA
Carboxylase (ACC) and Fatty Acid Synthase (FAS) [8].
The health impacts of high circulating cholesterol can be severe and affect a large portion
of the population. Macrophages take up cholesterol (associated with LDL) in the bloodstream
and export this cholesterol to HDL [9]. If circulating macrophages become too laden with
cholesterol, they transform into foam cells that collect along the walls of arteries in plaques and
2

can trigger a persistent inflammatory response. These ‘coatheromatous plaques’ contain necrotic
tissue, extracellular lipids, and immune cells. This condition is known as atherosclerosis, and
can lead to a variety of complications including stroke, myocardial infarction (heart attack)
resulting from coronary artery disease, and peripheral artery disease. In addition, this enduring
inflammatory response increases the risk of cancer, mainly by promoting angiogenic factors [10].
Despite age adjusted declines in atherosclerotic cardiovascular disease over the past two
decades [11], heart disease is still the most common cause of death in the United States, killing
about 610,000 people per year in the US [12]. The incidence rate remains high despite medical
advances due to the high level of cholesterol in the western diet. Limiting cholesterol intake in
the diet remains an effective form of prevention. Statins, such as mevinolin, are commonly
prescribed to control plasma cholesterol levels, and have had limited success in reducing
coatheromatous plaque volume [13]. Statins act as HMG-CoA reductase inhibitors, blocking
cellular production of cholesterol. Low cholesterol levels in the ER cause the activation of
SREBP2, which then upregulates LDL receptor. This leads to lower levels of LDL in the blood
and reduces the risk of atherosclerosis. However, these drugs have can have a variety of side
effects, including increased risks of muscular damage, hepatoxicity, stroke, and diabetes [14, 15].
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are another mechanism of
treating atherosclerosis [16], and is now in use for extreme cases of the disease. PCSK9
degrades the LDL receptor, preventing peripheral cells from taking in and recycling LDL.
PCSK9 inhibitors are monoclonal antibodies that bind to PCSK9, inhibiting it and preserving
LDL receptor.
Theoretically, increasing levels of HDL should allow macrophages to export more
cholesterol and prevent them from being embedded in artery walls. However, despite many
3

attempts at treating atherosclerosis by elevating HDL levels, so far this avenue of treatment has
received mixed results [17]. This could be due to a lack of understanding of HDL subtypes and
constituents, meaning more targeted treatments could see greater efficacy. Upregulating the
cholesterol efflux pathway to HDL could also be an effective alternative treatment to
atherosclerosis. Increasing the ability of macrophages to export cholesterol to HDL would
prevent their deterioration into foam cells and reduce the formation of plaques. In addition, this
could increase the elimination of cholesterol through bile acid synthesis by increasing HDL
transport of cholesterol to the liver. However, the mechanism of cholesterol efflux is not
completely understood.
ATP-Binding Cassette Transporter 1 (ABCA1) is the primary mechanism of cholesterol
efflux. ABCA1 is a membrane bound protein that acts as a cholesterol pump, transporting
intracellular cholesterol to lipoprotiens [18]. It has been shown that downregulation of ABCA1
in macrophages impairs cholesterol efflux and can lead to cardiovascular disease [19]. Tangier
Disease, a genetic disorder characterized by very low levels of HDL, is caused by a mutation in
ABCA1 [20]. ABCA1 transports cholesterol to lipoproteins by interacting with ApoA1, an
apolipoprotein associated with both HDL and LDL. ABCA1 is upregulated by the Liver X
Receptor (LXR), a nuclear transcription factor that acts as a receptor for oxysterols [5].
Oxysterols are produced in response to high free cholesterol levels, and in the presence of these
cholesterol derivatives, LXR is activated [21]. It is not known how cholesterol is brought to
ABCA1 to be transported out of the cell. Lipid rafts are regions of the plasma membrane that are
high in cholesterol; these domains play important roles in signal transduction, and may be
involved in cholesterol efflux. It has been shown that ABCA1 reduces free cholesterol content in
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lipid raft domains [22]. However, the role of lipid rafts in ABCA1 mediated cholesterol efflux
has been called into question [23].

5

Intracellular Cholesterol Transport

Cholesterol, when it is first taken in by the cell, is brought to the lysosomes and needs to
be distributed throughout the cell. The intracellular transport of cholesterol is important for the
uptake, efflux, and synthesis of cholesterol, and is necessary to maintain the fluidity and integrity
of the various cellular membranes. While much of intracellular cholesterol transport is mediated
by vesicles, non-vesicular mechanism represent a large portion of cholesterol transport and are
poorly understood [24].
Among the best understood proteins that play a role in intracellular cholesterol transport
is NPC-1. NPC-1 is a membrane bound protein found in the late endosomes. NPC-1 protein
allows for the transport of cholesterol from the late endosomes to the ER by translocating
cholesterol to outside the late endosome [25]. NPC-1 is upregulated by LXR [26]. Another well
understood intracellular cholesterol transport protein is StarD1. StarD1 was the first member
StarD protein family, which is characterized by the lipid binding StarD-related lipid transfer
(START) domain. StarD1 is localized to and carries cholesterol to the mitochondria [27]. The
homology of the START domain in StarD1 to the START domains of StarD4 and StarD5 led to
the discovery of these two proteins and the StarD4 protein sub-family [28].
Both StarD4 and StarD5 have been shown to bind cholesterol in vitro [29]. The two
proteins, being structurally dominated by their START domain, have a very high degree of
structural homology. StarD4 has been shown to transport cholesterol to the ER [30, 31], though
it is not clear if this transport is targeted to specific domain. It has also been linked to the
production of cholesterol esters by Acyl-CoA: cholesterol acyltransferase (ACAT) and the
formation of lipid droplets [31]. However, StarD4 has also been shown to play a role in the
6

transport of cholesterol between the plasma membrane and the endocytic recycling compartment
(ERC), which regulates the recycling of endosomal contents to the plasma membrane [24]. It is
clear that we do not yet have a complete picture of the role StarD4 plays in cholesterol transport.
StarD5 has a high level of expression in macrophages, which suggests that it may play a
role in cholesterol efflux to HDL. It is also highly expressed in cancer cells, where high levels of
cholesterol are needed for cell division. StarD5 is upregulated by the ER stress response via
stabilization of StarD5 mRNA and by the ER stress transcription factor XBP-1 [32]. The ER is
highly sensitive to changes in cholesterol metabolism, and changes in cholesterol homeostasis
can cause ER stress. ER stress triggers the unfolded protein response (UPR), a process that is
significant in many diseases [29, 32]. Both cholesterol and StarD5 move to the plasma
membrane of the cell during ER stress or, as shown in unpublished data in our lab, exposed to
lipoprotein deficient serum (LPDS). However there is no conclusive link between these two
movements. The mechanism by which StarD5 moves to the plasma membrane is unknown, as
are the proteins associated with StarD5, which could include chaperone proteins responsible for
the movement of StarD5. It is possible that StarD5 transports cholesterol to ABCA1 for export,
but this has not been confirmed.

7

Niemann Pick Type C Disease

The importance of the intracellular transport of cholesterol is most clear when errors in
intracellular cholesterol transport cause disease. Niemann Pick Type C (NPC) disease is a fatal
lysosomal cholesterol storage disease symptomatically identical but biochemically distinct from
Niemann Pick Types A and B. While types A and B are the result of a deficiency in the Acid
Sphingomyelinase protein, NPC is the result of a mutation in either the NPC-1 or NPC-2 protein
that drastically reduces (but does not completely eliminate) its activity. NPC disease occurs in
1:150,000 people [33] and typically presents in early childhood, with half of cases occurring by
10 years of age. Symptomatically, NPC disease is primarily a neurodegenerative disease. It is
characterized by dementia [34], ataxia [35], other progressive neurological problems, along with
a swelling of the liver. The cerebellum, the portion of the brain responsible for motor control, is
particularly affected by NPC [36].
Deficiency in NPC-1 results in cholesterol buildup in the lysosomes at the expense of
other regions of the cell, including the ER. The low levels of cholesterol in the ER activate
SREBP2, which upregulates the cholesterol biosynthesis pathway and causes overproduction of
cholesterol. The cholesterol buildup from NPC in the late endosomes is recognizable in cells
under a fluorescent microscope through filipin staining [37]. In addition, NPC should also
decrease the levels of cholesterol in the plasma membrane and in the ER, and a decline in ER
cholesterol should result in the increased expression of HMG-CoA reductase.
Treatment for NPC remains focused on managing symptoms and improving quality of
life. Miglustat has been shown to have some effectiveness at slowing neurological deterioration
[38], however no treatment has been developed that addresses the mechanism of NPC disease or
8

offers a chance of long term survival. There are a number of therapeutic strategies currently
under research. Hydroxypropyl β-cyclodextrins (HP-β-CDs) have shown promise in reducing
cholesterol in NPC-1 deficient cells [39]. This cyclic oligosaccharide contains a hydrophobic
interior pocket that can extract cellular cholesterol. HP-β-CDs have had success in ameliorating
the symptoms of NPC in animal and clinical trials, but have also been found to cause impaired
hearing. N-butyldeoxynojirimycin [40], a glucoceramide synthase inhibitor, and histone
deacetylase (HDAC) inhibitors have also been explored [41]. In particular, HDAC inhibitors
have been successful in combination with 2-HP-β-CD and polyethylene glycol in mouse models
[42]. HDAC inhibitors increase levels of NPC-1 protein, possibly through post-translational
stabilization, which allows it to move outside of the ER.
Both StarD4 and NPC-1 are believed to facilitate cholesterol transport to the ER. This
overlap in function raises the possibility that the overexpression of StarD4 could ameliorate the
effects of NPC disease. Histochemistry of StarD4 knockout liver samples demonstrate that there
are similarities between StarD4 knockouts and the NPC-1 mutant phenotype- both cells types
visibly accumulate lipids (Figure 1). Our lab has also seen the similarities between phenotypes
of NPC-1 mutant and StarD4 knockout cells under filipin staining, and have shown that
overexpression of StarD4 with a StarD4 adenovirus reverses the phenotype in NPC-1 mutant
cells (Figure 2). It is possible that this occurs because of StarD4 transport of lysosomal
cholesterol to the ER, which would lower cholesterol synthesis to normal levels.
These results raise the possibility that overexpression of StarD4 could ameliorate the
impacts of NPC disease. The overexpression of StarD5 could also potentially impact the NPC
phenotype. Research into how these proteins function is crucial for understanding the
intracellular transport of cholesterol as a whole, and is relevant to many diseases, including NPC
9

Figure 1. Histochemistry of WT and StarD4 KO mouse livers show lipid accumulation in
StarD4 knockout livers. StarD4 knockout mice (right) have white spots indicating neutral
lipids, which resembles what is seen in NPC-1 mutant cells. This accumulation of lipids is
clearer under a high fat ‘western diet’, where mice have a greater accumulation of lipids than
under a normal ‘chow diet’.
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Figure 2. StarD4 overexpression normalizes cholesterol distribution in NPC-1 mutant
fibroblasts. Panel A – Wild type astrocytes have low levels of free cholesterol under filipin
staining. Panel B – StarD4 knockout astrocytes higher levels of intracellular free cholesterol,
similar to NPC-1 mutant cells. Panel C – NPC-1 mutant fibroblasts infected with a control
adenovirus also have high levels of free cholesterol, similar to in StarD4 knockout astrocytes.
Panel D – Free cholesterol levels in NPC-1 mutant fibroblasts is lower after infection with a
StarD4 adenovirus.
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Materials & Methods

Materials
C57 BL/6J NPC-1 Mutant (nmf164) mice were ordered from Jackson Labs. Cell lines
used include HeLa cells and Chinese Hamster Ovary (CHO) wild type and 10-3 NPC-1 mutant
cells from the Liscum lab [43]. Primers and fluorescent probes for qPCR were ordered from
Integrated DNA Technologies (Table 1). Other general chemicals used were ordered from
Sigma.
Table 1. Primers and probes used for qRT-PCR experiments. .

Gene Name
Mouse NPC1
Mouse NPC1
Mouse NPC1
Mouse
StarD5
Mouse
StarD5
Mouse
StarD5
Human
StarD4
Human
StarD4
Human
StarD4
Mouse
ABCA1
Mouse
ABCA1
Mouse

ID
NM_008720
NM_008720
NM_008720
NM_023377.4
NM_023377.4
NM_023377.4
NM_00130805
6.1
NM_00130805
6.1
NM_00130805
6.1
NM_013454
NM_013454
NM_013454

Primer
Fwd.
Primer
Rev.
Primer
Probe

Nucleotides
1684-1707

Fwd.
Primer
Rev.
Primer
Probe

250-271

Fwd.
Primer
Rev.
Primer
Probe

370-391

Fwd.
Primer
Rev.
Primer
Probe

5899-5920

1764-1783
1723-1748

354-375
301-324

448-468
415-438

5984-6005
5952-5975
12

Sequence
CAAGTAGGCGACGACTTCTA
TATC
CGT
GGAGCAAACTCGTATCA
ACACACTTTCTGTACTGTGT
ACGGGC
CGGGAGAAGTGGGATGATA
ATG
CACAAAGTCCCTGGGAGAA
ATA
ACGGATATGCTGTGTGTGAG
CAGA
CTCTACAAAGCCCAAGGTGT
TA
AGTCATCAAGCTGTCCCAAT
C
ATAGACCATATACGCCCAG
GGCCT
GGGTGGTGTTCTTCCTCATT
AC
CACATCCTCATCCTCGTCAT
TC
CCCAGACCTGTAAAGGCGA

ABCA1

AGCTT

Mouse
HMGCR
Mouse
HMGCR
Mouse
HMGCR
Mouse
SREBP1
Mouse
SREBP1
Mouse
SREBP1
Mouse
SREBP2
Mouse
SREBP2
Mouse
SREBP2
Mouse FAS

BC085083

Mouse FAS

NM_007988

Mouse FAS

NM_007988

Mouse ACC

NM_133360.2

Mouse ACC

NM_133360.2

Mouse ACC

NM_133360.2

Mouse
GAPDH
Mouse
GAPDH
Mouse
GAPDH

NM_00128972
6
NM_00128972
6
NM_00128972
6

BC085083
BC085083
NM_00131397
9.1
NM_00131397
9.1
NM_00131397
9.1
AF374267.2
AF374267.2
AF374267.2
NM_007988

Fwd.
Primer
Rev.
Primer
Probe

1893-1915

Fwd.
Primer
Rev.
Primer
Probe

2041-2060

Fwd.
Primer
Rev.
Primer
Probe

1327-1345

Fwd.
Primer
Rev.
Primer
Probe

3523-3544

Fwd.
Primer
Rev.
Primer
Probe

6166-6187

Fwd.
Primer
Rev.
Primer
Probe

833-853

1987-2008
1917-1940

2102-2122
2075-2097

1403-1424
1346-1369

3600-3621
3568-3591

6256-6275
6221-6244

904-922
859-882

Virus Preparation
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CTGAAGGGTTTGCAGTGATA
AAG
CCTGGACTGGAAACGGATA
TAG
AGGCCTTTGATAGCACCAGC
AGAT
GCGGCTGTTGTCTACCATAA
CCAGGTTAGAAGCAGCAAG
AT
ATGCCATGGGCAAGTACAC
AGGA
TGGATGACGCAAAGGTCAA
CAGGAAGGTGAGGACACAT
AAG
ACAGGAGGAGAGTCCGGTT
CATCC
GCTATGATTATGGCCCTCAG
TT
CCATGAAGGTCACCCAGTTA
TC
TTGAAGGTGAACAAGGCAA
GCTGC
GTTTCTCTGGTGGGATGAAA
GA
GGGCGGGATGTAAACCATT
A
CATTGTGGATGGCTTGCGGG
AATG
GGAGAAACCTGCCAAGTAT
GA
TCCTCAGTGTAGCCCAAGA
TCAAGAAGGTGGTGAAGCA
GGCAT

To create the StarD4-AAV9 virus (Figure 3), the coding region of human StarD4 cDNA
was excised from the RC223123 plasmid (Origen) by EcoR1/XhoI digestion. This fragment was
inserted after a CMV promotor into the pAAV-IRES-hrGFP plasmid (Figure 4), which contains
the inverted repeats needed to make the AAV9 virus. This insertion was confirmed by HindIII,
EcorR1/XhoI, NotI, and SmaI digestion (Figure 5). Both a control and StarD4-AAV9 virus
were ordered from the Penn Vector Core. The AAV9 serotype was chosen for its ability to infect
both the liver and the brain, its ability to remain active for over a month post injection, and its
low inflammatory effect [44].
StarD1, StarD4, StarD5, and control adenoviruses were commonly used in the lab. In the
StarD1, StarD4, and StarD5 adenoviruses, the transcription of cDNA encoding the StarD protein
was driven by the human CMV promoter [45].

Figure 3. A scheme of the plasmid used to make the AAV9-StarD4 virus. .
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Figure 4. Insertion of the StarD4 cDNA fragment into the pAAV-IRES-hrGFP plasmid. .
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Figure 5. Restriction enzyme analysis of the pAAV-IRES-hrGFP-StarD4 plasmid by
digestion with EcoR1/XhoI, HindIII, NotI, and SmaI.
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StarD5-/- Mice Experiments
Wild type and StarD5-/- C57 BL/6J mice were fed a normal chow diet, a 2% cholesterol
diet for 5 days, or a Western Diet (the TD.88137 adjusted calories diet) for 8 weeks. Livers were
harvested and RNA was extracted. qRT-PCR was used to determine relative mRNA expression.
Peritoneal macrophages from wild type and StarD5-/- C57 BL/6J mice were harvested and RNA
was extracted for qRT-PCR.
Overexpression of StarD4 in NPC-1 Mutant Mice
NPC-1 nmf164 mutant mice were infected with 4x1012 pfu of StarD4-AAV9 virus or a
control virus using the orbital injection technique. Four weeks following the first injection, the
mice were injected with another 4x1012 pfu of StarD4 AAV9 virus. Ten days after each
injection, mice were tested for motor ability with the coat hanger test. Uninjected NPC-1 mutant
and wild type mice were also tested. Mice were allowed to grip a coat hanger suspended 8
inches above a counter top, and were allowed to hang until they fell off. If a mouse was able to
hang on for at least 2 minutes they were let down and 2 minutes was marked as their hang time
(Figure 6). Six weeks following the first injection, the mice were killed via cervical dislocation
and weighed. The brains and livers were harvested, and samples were used for cholesterol and
triglyceride quantifications and mRNA profiling by qRT-PCR.

17

Figure 6. The coat hanger test. .

RNA Extraction
RNA was harvested with either an RNeasy Plus Mini Kit (Quiagen) according to the
protocol provided by the kit, or with Trizol reagent (Ambion). For samples harvested with
Trizol reagent, 25 ng of tissue was weighed, homogenized, and incubated in 500 µL of Trizol
reagent for 5 minutes. 100 µL of chloroform was added to lysate, and incubated for 3 minutes.
Samples were spun down for 15 minutes at 12,000 rcf at 4 °C. The upper aqueous phase was
transferred to a new tube and 250 µL of isopropanol was added. These samples were incubated
for 10 minutes and then spun down for 10 minutes at 12,000 rcf at 4 °C. The pellet was washed
in 75% ethanol and spun down again for 5 minutes at 7,500 rcf at 4 °C. The supernatant was
removed and the pellet was left to dry for 10 minutes, before being resuspended in 50 µL of
RNase free water. The RNA from both extraction methods was quantified on a Nanodrop 2000c
(Thermo).
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mRNA Quantification
qRT-PCR was run with the Brilliant III Ultra-Fast QRT-PCR Master Mix kit (Agilent).
Each set of primers was calibrated using temperature and concentration curves. 500 nM of
EDTA was added to mixes for each gene except human StarD4. GAPDH was used as an internal
control for all samples, except human StarD4, where it was used as an external control. qRTPCR was run on a Realtime qPCR Cycler (CFX96, BioRad).
Total Cholesterol, Free Cholesterol, Triglyceride Quantification
Samples of livers and brains were suspended in lysis buffer at a ratio of 100 mg of tissue
per 700 µL of buffer, homogenized and lysed. 150 µL of the homogenates were then suspended
in 5 mL of 2:1 chloroform: methanol and incubated overnight. The samples were spun down and
the supernatant was aliquoted for use in lipid assays. 100 µL of each sample was dried under N 2
and used in kit assays for cholesterol (Cholesterol E, Wako), free cholesterol (Free Cholesterol
E, Wako), and triglycerides (Infinity Triglycerides, Thermo) following kit protocols. A Bradford
assay with BSA standards was used to quantify protein concentrations of the lysates. This data
was used to determine cholesterol and triglyceride concentrations per µg of protein.
Protein Quantification
Bradford Assays were used to determine protein concentrations. We used BioRad
Protein Assay Dye Reagent Concentrate diluted 1:5 in water as a Bradford reagent. Bovine
Serum Albumin (BSA) was used as a protein standard. The absorbance of the samples was
measured using a Biomate 3 Spectrophotometer at 595 nm (Thermo).
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Production of fALOD4* Cholesterol Probe
A fluorescent probe was used to quantify accessible plasma membrane free cholesterol
[46, 47]. We used ALOD4, the cholesterol binding fourth domain of the ALO protein from
Bacillus anthracis. In this experiment we used an ALOD4 mutant (ALOD4*) with two point
mutations (S404C and C472A), along with a His6 tag at the NH2 -end. These mutations allow
ALOD4* to more effectively bind to a fluorophore. Competent E. Coli cells were transformed
using a plasmid containing the ALOD4* sequence in front of the T7 promotor, which was given
to us by Dr. Arun Radhakrishnan [48]. Viable colonies were grown out to 6 L and induced with
1 mM IPTG at 30 °C for 16 hours. T7 polymerase is present in the genome of this E. Coli strain
and is regulated by the Lac operon. IPTG, a lactose mimic, induces production of T7 by binding
to the repressor, LacI. T7 will then rapidly transcribe ALOD4*, giving high yields of the
protein.
The cells were spun down at 5,000 rpm for 20 minutes and harvested in 120 mL of Buffer
B (50 mM Tris, 150 mM NaCl, 1mM DTT, 1mg/mL Lysozyme, 1X Pefabloc SC, and 0.5X
Protease Inhibitor Cocktail). Cells were lysed with a dounce homogenizer and then by a tip
sonicator (550 Sonic Dismembrator, Fisher Scientific) using five 30-second pulses up to setting
#7. The lysate was spun down for 1 hour at 45,000 rpm and the protein containing supernatant
was collected. 2 mL of an Ni-NTA agarose gel was washed in Buffer B with 50 mM imidazole
and the cell lysate was run through the Ni-NTA gel twice to capture ALOD4* protein. The
agarose gel was then washed with 20 mL of Buffer B with 50 mM imidazole and the protein was
eluted with 20 mL of Buffer B with 400 mM imidazole. 2 mL elution fractions were collected
and along with original lysate and flowthrough, were run on a 12% Acrylamide gel and stained
with coomassie blue dye. The elutions containing ALOD4* were pooled and the imidazole
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concentration was diluted to 50 nM via filtration using the Amicon Ultra-15 Centrifuge Filter kit
(Millipore). The pooled sample was run through a Ni-NTA column again, and eluted in 400 nM
imidazole. Protein was labelled with fluorescent Alexa Fluor 488 C 5 -maleimide dye by rotating
200 nmol of protein with 1400 nmol of fluorescent dye overnight at 4°C. Fluorescently labelled
ALOD4* is referred to as fALOD4*. Unbound dye was removed by concentration and dilution
using the Amicon Ultra-15 Centrifuge Filter kit (Millipore). In order to ensure that the
fluorescent dye bound to ALOD4*, fALOD4* was run on two 12% acrylamide gels. One gel
was stained with coomassie blue; the other was fluorescently imaged with a ChemiDoc MP
Imaging System (BioRad).
Quantification of Plasma Membrane Cholesterol by FACS Analysis of fALOD4*
Wild type CHO and NPC-1 10-3 mutant cells were harvested in 0.25% trypsin or
Accutase cocktail (eBioscience) and suspended in Buffer D (PBS with 1mM EDTA and 2%
LPDS) at a concentration of 1 million cells per mL. Cells were incubated by rotating with the
indicated amounts of fALOD4* for 3 hours at 4 °C in darkness. The fluorescently labelled cells
were washed with PBS, spun down for 2.5 minutes at 2,5000 rcf, and suspended in PBS for flow
cytometry (FACS) analysis.
Overexpression of StarD5 in NPC-1 Mutant Mice
NPC-1 mice were injected with a total of 4.23x1010 of StarD5 adenovirus by five orbital
injections over the course of three days. Three and seven days after the first injection, the livers
of these mice were harvested for cholesterol/triglyceride quantification and qRT-PCR.
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Protein Detection by Western Blot
Protein samples were denatured in sample buffer (20 mM Tris, 114 mM βMercaptoethanol, 6% Glycerol, 0.002% Bromophenol Blue, and 2.1% SDS), boiled for 10
minutes, and loaded into a 12% acrylamide gel. The protein was run on the gel in running buffer
(25 mM Tris, 190 mM glycine, 0.1% SDS) for 25 minutes at 120V and 25 minutes at 160V. An
immunobilon-P membrane was soaked in methanol for 5 minutes and transfer buffer (25 mM
Tris, 190 mM glycine, 20% methanol) for 5 minutes. The proteins were then transferred to the
membrane in transfer buffer for 50 minutes at 11V using a semi-dry transfer method.
Membranes were blocked in PBS with 0.1% Tween 20 (PBST) and 5% Instant Nonfat
Dry Milk (Nestle) for 2 hours and incubated with a primary antibody in PBST with 2.5% Instant
Nonfat Dry Milk at 4 °C overnight. Membranes were washed three times in PBST for 10
minutes each and incubated in PBST with Instant Nonfat Dry Milk and a secondary antibody for
1 hour at room temperature. Membranes were washed three times in PBST for 10 minutes each
and incubated for 1 minute in darkness in Western Lighting reagents (Perkins-Elmer). Images
were taken with the chemi-high resolution mode on the Chemi-Dock XLS+ (BioRad).
Protein Detection by Coomassie Stain
Protein samples were denatured in Sample buffer, boiled for 10 minutes, and loaded into
a 12% acrylamide gel. These samples were run on the gel in running buffer for 30 minutes at
120V. The gel was incubated in fixing solution (50% methanol, 10% acetic acid) for 1 hour, and
stained in staining solution (0.1% Coomassie Blue R-250, 50% methanol, 10% acetic acid) for
20 minutes. The gel was then destained in destaining solution (40% methanol, 10% acetic acid),
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decanting as solution becomes colored, and left to destain overnight. Imaging was done on the
Chemi-Dock XLS+ (BioRad) with the coomassie stain mode.
Immunoprecipitation (IP)
HeLa cell cultures were infected with 2000 viral particles of StarD5 adenovirus and
incubated in either 10% FBS or 10% LPDS media. HeLa cells were also infected with 2000
viral particles of a control adenovirus and incubated in 10% FBS media. Cells were harvested by
scraping in PBS, and some samples were crosslinked with formaldehyde to link StarD5 to any
associated proteins. To crosslink, cells were suspended PBS with 1% formaldehyde for 10
minutes at a concentration of 1x107 cells per mL. Formaldehyde was quenched with PBS with
125 mM glycine.

All samples were then lysed with Lysis Buffer (20mM Tis-HCl, 150mM

NaCl, 1mM EDTA, 0.5% NP40 pH 7.4, and 1% protease inhibitor cocktail from Bimake).
To isolate StarD5 and its potential chaperones, the lysate was then purified via an
immunoprecipitation process. The lysate was cleaned by rotating 600 µL of lysate with 40 µL of
an anti-HA agarose gel (Sigma) for 30 minutes at 4 °C. Then the lysate was passed through 40
µL of anti-flag affinity gel (Bimake) overnight at 4 °C to capture StarD5 and associated proteins.
The agarose was washed three times with 500 µL of Lysis Buffer and eluted with 150 ng/µL
Flag Peptide (Sigma-Aldrich) by rotating for 30 minutes at 4 °C. The agarose was then treated
with sample buffer and boiled for 10 minutes to collect any remaining protein. Samples were
then run on a 12% acrylamide gel and stained with coomassie dye.
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Results

My research consists of four projects. 1- The characterization of mRNA expression profiles
in StarD5-/- mice. 2- Exploration of the potential use of StarD4 to ameliorate the NPC phenotype
in vivo, and investigating StarD4 overexpression as a potential therapy. 3- Exploration of the
potential of StarD5 to overcome the NPC phenotype in both in vitro and in vivo models. 4Beginning the process of characterizing potential chaperone proteins for StarD5.

1- Wild Type and StarD5-/- Mice Have Different Gene Expression Profiles

Genes Involved in Cholesterol Metabolism and Transport Have Altered mRNA Expression in
StarD5-/- Mouse Livers
As a part of the characterization of StarD5 -/- mice developed in our lab, we extracted
RNA from the livers of wild type and StarD5 -/- mice. The relative mRNA expression of key
genes involved in cholesterol metabolism and transport were quantified by qRT-PCR (Figure 7).
As expected, StarD5-/- mouse livers had no expression of StarD5 mRNA. mRNA expression in
StarD5-/- mouse livers was significantly different from in wild type livers for four other genes,
ABCA-1, HMG-CoA reductase, NPC-1, and FAS. StarD5-/- mouse livers have a higher level of
expression of ABCA-1 than in wild types– 160% of wild type livers. StarD5-/- mouse livers also
have a higher level of NPC-1 expression, at 210% of wild type liver expression. Other genes had
lower levels of expression in StarD5-/- mouse livers, like HMG-CoA reductase where StarD5-/mice had 70% of the expression of wild type livers. FAS mRNA expression in StarD5-/- mouse
livers was 50% of wild type expression.

In the other genes we tested, wild type and StarD5 -/-
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mouse livers did not have significant differences in mRNA expression. These genes include
SREBP2, where StarD5-/- mouse livers had about 125% of the mRNA expression of wild types.
StarD5-/- mouse livers had 160% of the mRNA expression of ACC and 230% of the expression
of StarD4 compared to wild type livers, however these differences were not statistically
significant.
Genes Involved in Cholesterol Metabolism and Transport do not Have Altered mRNA Expression
in StarD5-/- Mouse Macrophages
RNA was also extracted from macrophages harvested from wild type and StarD5-/- mice.
qRT-PCR was used to quantify the relative mRNA expression of genes involved in cholesterol
transport and metabolism. We found wild type and StarD5 -/- macrophages did not have
significantly different mRNA expressions in any of the genes we tested (Figure 8). In StarD5-/macrophages, ABCA-1 HMG-CoA reductase, SREBP1, SREBP2, NPC-1, and ACC had 140%,
130%, 90%, 100%, 90%, and 140% of the mRNA expression found in wild types.
StarD5-/- and Wild Type Mice Have Similar mRNA Expression Profiles Under a High
Cholesterol Diet
We next tested how gene expression changed in response to diet in wild type and
StarD5-/- mice. StarD5-/- and wild type mice were fed either a western diet for 8 weeks or a 2%
cholesterol diet for 5 days. RNA was extracted from the livers of these mice, and the mRNA
concentration of genes involved in cholesterol transport and metabolism was quantified using
qRT-PCR. In mice that were fed a 2% cholesterol diet, we found that while the mRNA
expression profile changed compared to mice that had been fed a chow diet (Figure 9), wild type
and StarD5-/- mice had very similar levels mRNA expression for all genes tested (Figure 10).
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This pattern holds true even for genes where StarD5 -/- and wild type mice had very different
levels of mRNA expression in wild type mice. In addition, we see that several genes, such as
FAS, are less sensitive to changes in the cholesterol content of the diet. In wild type mice FAS
mRNA expression drops 5-fold in mice fed a 2% cholesterol diet, while in NPC-1 mutant mice
FAS mRNA expression increases by 20% in mice fed a 2% cholesterol diet.
In the livers of mice that were fed a western diet, we again saw the expected changes in
mRNA expression compared to mice that were fed a chow diet. We also found that in three
genes, wild type StarD5-/- mice differed in mRNA expression. For SREBP2, we found that the
livers StarD5-/- mice had 50% the mRNA expression of wild type mice. For ACC, we found that
the livers of StarD5-/- mice had 260% the mRNA expression of wild type mice. For FAS, the
livers of StarD5-/- mice had 70% the mRNA expression of FAS that we found in wild type mice.
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Figure 7. Relative mRNA expression levels in StarD5-/- and wild type livers. Panel AABCA1, HMG-CoA reductase, NPC-1, StarD5, and FAS mRNA expression levels. Panel BSREBP2, ACC, and StarD4 mRNA expression levels. * - P<0.1. n = 3.
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Figure 8. Relative mRNA expression in StarD5 -/- and wild type macrophages. Relative
mRNA expressions of ABCA1, HMG-CoA reductase, SREBP1, SREBP2, NPC-1, and ACC.
None of the genes tested showed a statistically significant change in mRNA expression in
macrophages. n = 1.
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Figure 9. Relative mRNA expression levels in mouse livers in response to being fed a chow
diet or a 2% Cholesterol diet for 5 days. Panel A – Relative mRNA expression of wild type
mice fed a chow diet or a 2% cholesterol diet. Panel B – Relative mRNA expression of StarD5-/mice fed a chow diet or a 2% cholesterol diet. * – P<0.1, ** – P<0.05, *** – P<0.01. n = 3.
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Figure 10. Relative mRNA expression levels for StarD5-/- and wild type mouse livers in
response to diet. Panel A - The mRNA expression in wild type and StarD5-/- mice in response
to being fed a western diet for 8 weeks. Panel B - The mRNA expression in wild type and
StarD5-/- mice in response to being fed a 2% Cholesterol diet for 5 days. * – P<0.1. n = 3.
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2- Overexpression of StarD4 Ameliorates the NPC Phenotype in Mice

StarD4 Overexpression Improves Motor Ability in NPC-1 Mutant Mice as Measured by the Coat
Hanger Test
As described in the introduction, knocking out StarD4 in macrophages causes cells to
display similar cholesterol levels and distribution as NPC-1 mutant cells (Figure 1). In addition,
overexpression of StarD4 appears to normalize the cholesterol distribution in NPC-1 mutant
macrophages (Figure 2). For these reasons, StarD4 overexpression was chosen as a potential
therapeutic treatment to ameliorate the NPC phenotype. NPC-1 mutant mice were infected with
an AAV9-StarD4 virus as described in the Methods section. Ten days following each infection,
mice were tested for motor ability with the coat hanger test. Wild type mice had significantly
longer hang times than uninfected NPC-1 mutant mice (Figure 11). Mice infected with AAV9StarD4 virus also had longer hang times over uninfected NPC-1 mutant mice. Wild type mice
hung for an average of 90 seconds, uninfected NPC-1 mutants mutant hung on for 52 seconds,
NPC-1 mutants infected with an AAV9-control virus hung for 56 seconds, NPC-1 mutants
infected with AAV9-StarD4 hung for 67 seconds following the first injection and 74 seconds
after the second injection.
AAV9-StarD4 Virus Increased Expression of StarD4 in Mouse Livers and Brains
Protein was extracted from the liver samples of uninfected NPC-1 mutants and NPC-1
mutants infected with AAV9-StarD4. These samples run on an acrylamide gel and
immunoblotted with a western blotting technique to identify human StarD4 protein. We found
that AAV9-StarD4 infected mice expressed 3-fold higher levels of StarD4 protein than in
uninfected mutant mice (Figure 12). In addition, we ran qRT-PCR to quantify the expression of
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human StarD4 mRNA in the brains of AAV9-StarD4 infected and uninfected NPC-1 mutants.
We found that AAV9-StarD4 infected mice had roughly 160% higher mRNA expression of
StarD4 than uninfected mice. Despite detecting endogenous StarD4 in both of these tests, these
results indicate that infection with AAV9-StarD4 does increase expression of StarD4 in the liver
and brain.
Overexpression of StarD4 Does not Impact the mRNA Expression Profile of Key Genes Involved
in Cholesterol Metabolism and Transport
RNA was extracted from the livers and brains of wild type mice, NPC-1 mutant mice that
were not infected with a virus, NPC-1 mutant mice that were infected with AAV9-control virus,
and NPC-1 mutant mice infected with AAV9-StarD4 virus. The relative mRNA expressions of
HMG-CoA reductase, ABCA1, and NPC-1, were quantified by qRT-PCR (Figure 13). We
found that mice injected with the AAV9-StarD4 virus did not have significantly different mRNA
expression from uninjected or AAV9-control virus injected mice for any of the three genes. In
the liver, both uninfected and AAV9-StarD4 infected NPC-1 mutants had 170% of the HMGCoA reductase mRNA expression of wild type mice.
In the brain, HMG-CoA reductase mRNA expression was unchanged between wild types
and uninfected NPC-1 mutants; uninfected NPC-1 mutants were at 95% of the HMG-CoA
reductase expression of wild types. We also found no difference in ABCA1 mRNA expression
between wild types and uninfected NPC-1 mutant. NPC-1 levels show a slight correlation. In
AAV9-StarD4 infected NPC-1 mutants, mRNA expression of NPC-1 is 90% of that in wild
types. This is compared to uninfected NPC-1 mutants and NPC-1 mutants infected with AAV9-
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control virus, which have NPC-1 mRNA expression at about 60% of wild type expression.
However, this slight difference is not statistically significant.
Cholesterol and Triglyceride Levels Decrease is Response to StarD4 Overexpression in NPC-1
Mutant Mice
To further explore the impact of StarD4 overexpression on the NPC phenotype, we
measured triglyceride, free, and total cholesterol from brain and liver samples of NPC-1 mutant
mice. We found that NPC-1 mutant mice infected with AAV9-StarD4 virus had lower levels of
total and free cholesterol than uninfected NPC-1 mutant mice. In the liver (Figure 14), AAV9StarD4 injected NPC-1 mutants have 0.8 ng of total cholesterol per µg of protein while
uninjected NPC-1 mutants have 1.7 ng/µg of protein. Free cholesterol levels are very similarAAV9-StarD4 injected NPC-1 mutants have 0.7 ng of free cholesterol per µg of protein, while
uninjected NPC-1 mutants have 1.6 ng/µg of protein.
Brain cholesterol levels also show this pattern (Figure 15). AAV9-StarD4 injected NPC1 mutants have 4.7 ng of total cholesterol per µg of protein while uninjected NPC-1 mutants
have 13.1 ng/µg of protein. Again, free cholesterol levels are very similar to total cholesterol
levels- AAV9-StarD4 injected NPC-1 mutants have 5.1 ng of free cholesterol per µg of protein,
while uninjected NPC-1 mutants have 13.1 ng/µg of protein.
Triglyceride levels followed a similar pattern in the liver but not in the brain. In the liver
NPC-1 mutants injected with AAV9-StarD4 virus had 1.8 ng of cholesterol per µg of protein,
while uninfected NPC-1 mutants had 5.3 ng of triglycerides per µg of protein.
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Figure 11. StarD4 overexpression improves motor ability in NPC-1 mutant mice. Wild
Type, NPC-1 mutant mice, NPC-1 mutant mice injected with AAV9-control virus, and NPC-1
mutant mice injected with AAV9-StarD4 virus as described in methods were subjected to the
coat hanger test to test their motor abilities. Wild type – n=7, NPC-1 mutants – n=7, AAV9Control – n=3, AAV9-StarD4 (1) – n=7 AAV9-StarD4 (2) – n=6.
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Figure 12. AAV9-StarD4 infection increases StarD4 expression in NPC-1 mutant mouse
livers and brains. Panel A, Lane 1 – Liver from an NPC-1 mutant mouse infected with AAV9control virus. Lane 2 - Liver from an NPC-1 mutant mouse harvested after the first AAV9StarD4 virus injection. Lane 3 - Liver from an NPC-1 mutant mouse harvested after the second
AAV9-StarD4 virus injection. Panel B – Relative mRNA expression of StarD4 in the brain
between uninjected NPC-1 mutants and AAV9-StarD4 Injected NPC-1 mutants. NPC-1 mutant
– n = 4, AAV9-StarD4 Injected – n = 7.
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Figure 13. Relative mRNA expression of genes in wild type, uninfected NPC-1 mutant mice,
AAV9-control virus infected NPC-1 mutant mice, and AAV9-StarD4 virus infected NPC-1
mutant mice. Panel A – Relative mRNA expression of genes in the liver. Panel B – Relative
mRNA expression of genes in the brain. Wild type - n=4, NPC-1 Mutant - n=4, StarD4
Injected - n=7, Control Injected - n=3.
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Figure 14. Total cholesterol, free cholesterol, and triglyceride concentrations of uninfected
and StarD4 infected NPC-1 mutant mice in the liver. * – P<0.1. Uninjected mutants - n=4,
AAV9-StarD4 injected - n=7.
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Figure 15. Total and free cholesterol concentrations of uninfected and StarD4 infected
NPC-1 mutant mice in the brain. * – P<0.1, ** – P<0.05. Uninjected mutants - n=4. StarD4
injected - n=7.

38

3- StarD5 Overexpression Ameliorates the NPC Phenotype

ALOD4* Purification and Labelling
As described in the Methods section, Ni-NTA column fractions were run on an
acrylamide gel and stained with coomassie blue dye in order to identify which fractions
contained ALOD4* protein (Figure 16). We found that most of the ALOD4* was being eluted
between the second and sixth elution. We also stained the original lysate and flowthrough,
confirming that most of the ALOD4* had been captured by the column. Following the labelling
process, fALOD4* was run on an acrylamide gel for coomassie staining and fluorescent
imaging. The protein was detected by both methods (Figure 17), confirming that the protein
was fluorescently labelled.
NPC-1 Mutant CHO Cells Have Reduced Levels of Accessible Plasma Membrane Cholesterol
Compared to CHO Wild Types
The results presented in this and the following section were selected from a set of
representative experiments. We first used fALOD4* to determine the differences in accessible
plasma membrane cholesterol levels between wild type CHO and NPC-1 10-3 mutant CHO cells.
1.6x106 wild type and 8x105 NPC-1 mutant cells were grown on 100 mm plates and harvested by
incubating in 0.25% trypsin for 10 minutes. Cells were incubated in a series of fALOD4*
concentrations and processed by flow cytometry (Figure 18). We found that wild type CHO
cells had roughly 2-fold higher levels of accessible plasma membrane cholesterol than NPC-1
mutant CHO cells.
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StarD5 Overexpression Increases Accessible Plasma Membrane Cholesterol Levels in Wild Type
and NPC-1 Mutant CHO Cells
Next, we looked at the impacts of infecting CHO cells with STAR domain proteins on
accessible plasma membrane cholesterol. CHO Wild type and NPC-1 10-3 mutant cells were
either left uninfected or infected with 3000 viral particles of StarD5 and StarD4 adenovirus and
harvested by incubating in accutase cocktail for 5 minutes. This was done to control the impact
of proteolytic cleavage on staining by fALOD4*. More aggressive cleavage techniques could
expose cholesterol domains that would ordinarily not be reached by fALOD4*, or could remove
the most exposed domains entirely. Accutase is a less aggressive proteolytic cocktail that
offered a greater degree of consistency in this experiment.

Lysates of CHO cells were run on an

acrylamide gel and immunoblotted with a western blotting technique, in order to detect
overexpression of StarD4 and StarD5 (Figure 19). We found that cells infected with a StarD4
adenovirus had higher levels of StarD4 protein, while cells infected with a StarD5 adenovirus
had higher levels of StarD5 protein.
We once again found that wild type CHO cells had 2-fold higher levels of accessible
plasma membrane cholesterol than NPC-1 mutant CHO cells. StarD4 infected wild types and
StarD4 infected mutants had very similar accessible plasma membrane cholesterol levels
compared to uninfected cells (not shown). However, StarD5 overexpression dramatically
increased accessible plasma membrane cholesterol levels. StarD5 overexpression caused a
greater increase in accessible plasma membrane cholesterol in wild type cells, where StarD5
overexpression caused an 11-fold increase in accessible plasma membrane cholesterol levels,
compared to mutants, where StarD5 overexpression caused a roughly 4-fold increase in
accessible plasma membrane cholesterol levels (Figure 20).
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The Overexpression of StarD5 Lowers the mRNA Expression of HMG-CoA Reductase in NPC-1
Mutant Mice
The success of increasing accessible plasma membrane cholesterol levels by
overexpressing StarD5 in CHOs led us to attempt a preliminary experiment in which StarD5 was
overexpressed in NPC-1 mutant mice using a StarD5 adenovirus. Two mice were injected five
times over the course of three days with a total of 4.23x10 10 StarD5 adenovirus. One mouse was
harvested three days after the first injection. The second mouse was harvested seven days after
the first injection. RNA was extracted from the livers of the two infected NPC-1 mutant mice as
well as livers of same-age uninfected NPC-1 mutant mice. We used qRT-PCR to determine the
relative mRNA expression of three genes (Figure 21). HMG-CoA reductase mRNA expression
was markedly lower in the StarD5 injected NPC-1 mutant mice than in uninfected NPC-1 mutant
mice. The NPC-1 mutant mouse harvested 3 days after the initial injection had 38% the HMGCoA reductase expression of uninfected NPC-1 mutant mice, while the NPC-1 mutant mouse
harvested 7 days after infection had an even lower level of expression, at 22%. We did not see
any differences in the mRNA expression of uninfected NPC-1 mutants and StarD5 infected
mutants for ABCA-1 and NPC1. The StarD5 infected NPC-1 mutants harvested 7 days after
infection had 78.7% of the expression of NPC-1 mRNA and 117% of the expression of ABCA-1
mRNA compared in uninfected NPC-1 mutant mice.
The Overexpression of StarD5 Lowers Cholesterol and Triglyceride Levels in NPC-1 Mutant
Mice
We measured the total cholesterol and triglyceride concentrations in the livers of
uninfected and StarD5 infected NPC-1 mutant mice. We found that the mouse harvested 7 days
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after infection with StarD5 adenovirus had much lower levels of cholesterol and triglycerides
compared to uninfected NPC-1 mutants. Uninfected NPC-1 mutant livers had 1.1 ng of
cholesterol per μg of protein, while StarD5 infected NPC-1 mutants had 0.5 ng/μg of protein.
Similarly, uninfected NPC-1 mutant livers had 4.6 ng of triglycerides per μg of protein, while
StarD5 infected NPC-1 mutants had 1.8 ng/ μg of protein.
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Figure 16. Coomassie staining of the ALOD4* purification process. Lane 1 - Ladder. Lane
2 – Cell lysate before running through Ni-NTA column. Lane 3 - Flowthrough of the Ni-NTA
column. Lanes 4-10: 2 mL fractions of ALOD4* eluted in 400 mM imidazole.

43

Figure 17. Fluorescent imaging and coomassie staining of fALOD4*. Panel A - 100 ng of
fALOD4* was ran on a 12% acrylamide gel and imaged for fluorescence. Panel B - Coomassie
staining of fALOD4*.
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Figure 18. Quantification of accessible plasma membrane cholesterol in CHO wild type
and NPC-1 10-3 mutant cells. A concentration curve of fALOD4* was used to quantify
accessible plasma membrane cholesterol in CHO wild type and NPC-1 mutant cells.
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Figure 19. Western blots of protein extracts from CHO cells used to detect overexpression
of StarD proteins by infection with adenovirus. CHO wild type cells were infected with
StarD4 and StarD5 adenovirus. Lysates from these cells were stained with antibody specific to
StarD4, StarD5, and β-Actin.
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Figure 20. Quantification of accessible plasma membrane cholesterol in CHO wild type and
NPC-1 10-3 mutant cells infected with StarD5 adenovirus. A concentration curve of
fALOD4* was used to quantify accessible plasma membrane cholesterol in wild type and NPC-1
mutant CHO cells that were uninfected or infected with StarD5 adenovirus.
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Figure 21. Relative mRNA expression in the livers uninjected and StarD5 injected NPC-1
mutant mice. qRT-PCR was used to determine the relative mRNA expression of HMG-CoA
reductase, NPC-1, and ABCA1 in uninjected and StarD5 injected NPC-1 mutant mice.
Uninjected - n=2, 3 Days After Injection - n=1, 7 Days After Injection - n =1.
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Figure 22. Total cholesterol and triglyceride concentrations of uninfected and StarD5
infected NPC-1 mutant mice in the liver. Uninfected NPC-1 mutants - n=2, StarD5 infected
NPC-1 mutants - n=1.
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4- Characterization of StarD5 Chaperone Proteins

Immunoprecipitation of StarD5 and Associated proteins from HeLa Cells Infected with a StarD5
Adenovirus
While we have found that overexpressing StarD5 can have impacts on plasma membrane
and possibly ER cholesterol levels, there are gaps in our understanding of StarD5 mediated
cholesterol transport. StarD5 does not have any known chaperone proteins, and identifying these
chaperones would shed light on how StarD5 moves around the cell and transports cholesterol.
To investigate this, we infected HeLa cells with a StarD5 adenovirus and incubated in either FBS
or LPDS media. We also infected HeLa cells with a control adenovirus and incubated those in
FBS media. For each treatment we treated a set of HeLa cells with formaldehyde to crosslink
StarD5 to nearby proteins. We used immunoprecipitation to capture StarD5 and any associated
proteins, ran the purified protein extracts on an acrylamide gel and stained them with coomassie
dye (Figures 23, 24).
In addition to the main StarD5 band, many much fainter bands were detected above
StarD5 in both gels. The bottom band is the Flag peptide used to elute the protein. Mass
Spectrometry analysis of these fainter bands in the gel in Figure 24 identified a large number of
proteins in these faint upper bands (Figure 25). A few of the most promising candidates for a
StarD5 chaperone protein were selected for consideration in future studies (Table 2).
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Figure 23. Lysates of StarD5 infected HeLa cells were purified by IP to isolate StarD5 and
its potentially associated proteins. Lane 1 – Ladder. Lane 2 - 50 ng BSA standard. Lane 3 100 ng BSA standard. Lane 5 – HeLa cells infected with a control adenovirus and incubated in
FBS media. Lane 7 - HeLa cells infected with a StarD5 adenovirus and incubated in FBS media.
Lane 9 – Hela cells infected with a StarD5 adenovirus and incubated in LPDS media.

51

1

2

3

5

7

9

Lane

Figure 24. Lysates of StarD5 infected, formaldehyde crosslinked HeLa cells were purified
by IP to isolate StarD5 and its potentially associated proteins. Lane 1 - Ladder. Lane 2 - 50
ng BSA standard. Lane 3 - 100 ng BSA standard. Lane 5 – HeLa cells infected with a control
adenovirus and incubated in FBS media. Lane 7 - HeLa cells infected with a StarD5 adenovirus
and incubated in FBS media. Lane 9 – Hela cells infected with a StarD5 adenovirus and
incubated in LPDS media.
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Figure 25. Samples from the coomassie stained gel were analyzed by MS for StarD5
associated proteins. Protein p-Value is the confidence that the protein is present. pValues
below 5 indicate low confidence in the presence of protein. The numbers in the 5th and 6th
columns indicate the number of unique peptides detected and (in parenthesis) the total number of
times these peptides were scanned for cells incubated in FBS and LPDS respectively.
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Table 2. Candidates for StarD5 Chaperone Proteins, chosen from proteins in Figure 25.
Protein p-Value is the confidence that the protein is present. pValues below 5 indicate low
confidence in the presence of protein. The numbers in the 4 th and 5th columns indicate the
number of unique peptides detected and (in parenthesis) the total number of times these peptides
were scanned for cells incubated in FBS and LPDS respectively.
Protein
TRK-fused
Low density lipoprotein related
protein 1B
ATP-binding cassette, sub-family
C, member 9 isoform
Ankyrin 3 isoform 1

ID
NP_001007566.1
NP_061027.2

p-Value
7.235
5.995

FBS
3 (5)
4 (4)

LPDS
1 (1)
1 (1)

NP_064693.1

5.783

2 (2)

2 (2)

NP_066267.2

5.763

2 (2)

3 (3)
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Discussion

Gene expression analysis of the StarD5 -/- mice shows that they have a lower HMG-CoA
reductase mRNA expression, and a higher NPC-1 and ABCA1 mRNA expression. These
responses correlate with our understanding of StarD5. Without StarD5, cholesterol accumulates
inside the cells and possibly in the ER. A high level of ER cholesterol would prevent the
activation of SREBP-2, which would trigger downregulation of HMG-CoA reductase. mRNA
expression of ABCA1 and NPC-1 is likely increased due to upregulation by LXR, which is
activated by oxysterols produced in response to high levels of free cholesterol.
Interestingly, when mice were fed a 2% cholesterol diet we do not see the same pattern
of mRNA expression. For example, in StarD5-/- mice FAS mRNA expression is unchanged in
response to a 2% cholesterol diet. Under a 2% cholesterol diet, wild type and StarD5-/- mice had
a similar level of mRNA for every gene we tested. This is likely because when mice are fed a
2% cholesterol diet, there are high levels of intracellular cholesterol in both wild type and
StarD5-/- mice. High levels of cholesterol trigger same regulatory pathways in both mouse
strains, leading to the same regulatory patterns.
In macrophages StarD5-/- and wild type mice have similar levels of mRNA in all of the
genes we tested. StarD5 is highly expressed in macrophages, so knocking out StarD5 was
expected to affect mRNA expression in these cells. This lack of response in macrophages
suggests that despite its high expression in this cell type, StarD5 is not as important in
macrophages as had been previously thought.
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NPC-1 mutant mice infected with AAV9-StarD4 virus had improved motor ability over
uninfected and AAV9-control virus infected mutants, as demonstrated by the coat hanger test.
These results are supported by the cholesterol and triglyceride levels. AAV9-StarD4 injected
NPC-1 mutant mice had lower levels of total and free cholesterol than uninjected NPC-1 mutant
mice in both the liver and the brain. There is a decrease in the level triglycerides in the liver, but
not in the brain. However, in the brain the NPC phenotype is most apparent in the cerebellum
[36]. We did not isolate regions of the brain, so we do not have a complete picture of how
StarD4 overexpression affects the NPC phenotype in the brain.
The results from the behavioral test and cholesterol assays suggest that overexpression of
StarD4 affects the NPC phenotype. It was anticipated that changes in motor ability and lipid
levels would be accompanied by a change in mRNA expression. However, our qRT-PCR
experiments gave some unexpected results. Mice infected with AAV9-StarD4 did not have a
significantly altered mRNA expression for any of the genes tested, aside from StarD4 itself.
This raises the question of where exactly StarD4 is transporting cholesterol to within the cell,
since the transport of cholesterol in the ER would normally result in the downregulation of
HMG-CoA reductase. StarD4 may be transporting cholesterol to a specific ER domain where it
does not affect HMG-CoA reductase expression. Another possibility is that StarD4 is
transporting cholesterol to the endocytic recycling compartment. It is important to note that this
experiment only involved seven AAV9-StarD4 infected mice, so these anomalous results could
disappear with a higher sample size.
The NPC phenotype is detectable in CHO cells through accessible plasma membrane
cholesterol levels. Quantification of accessible plasma membrane cholesterol with fALOD4*
revealed that wild type CHOs have more accessible plasma membrane cholesterol than NPC-1
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mutants. This was expected- NPC disease causes on accumulation of cholesterol in the late
endosomes while cholesterol levels in the ER and plasma membrane decrease. We also found
that overexpression of StarD5 with a StarD5 adenovirus in CHO cells dramatically increases
accessible plasma membrane cholesterol levels. This is the most convincing evidence yet that
StarD5 transports cholesterol to the plasma membrane. StarD5 triggers a much larger increase in
accessible plasma membrane cholesterol in CHO wild types than in NPC-1 mutants, which
suggests that cholesterol is not being transported from the late endosomes. NPC-1 mutants have
high levels of cholesterol in the late endosomes, so if StarD5 transported cholesterol from the
late endosomes one would expect that the overexpression of StarD5 would trigger a larger
increase in accessible plasma membrane cholesterol in NPC-1 mutants.
In NPC-1 mutant mice, we found that the overexpression of StarD5 with a StarD5
adenovirus reduced HMH-CoA reductase mRNA expression in the liver. This is accompanied
by a decrease of cholesterol and triglycerides in the liver in response to StarD5 overexpression.
It should be noted that this is a very preliminary experiment, involving only two infected mice.
Regardless, these results are very promising and indicate that overexpression of StarD5 has the
potential to treat NPC. A decline in HMG-CoA reductase expression suggests that cholesterol
levels in the ER increased in response to StarD5 overexpression. This is contrary to what would
be expected if cholesterol was being transported from the ER to the plasma membrane. The
results of our CHO experiments, while using a different cell type, suggest that StarD5 is not
taking cholesterol from the late endosomes either. The endocytic recycling compartment is a
likely candidate for a source of cholesterol for StarD5 mediated cholesterol transport, as it is rich
in cholesterol and StarD4 has been shown to transport cholesterol from it to the plasma
membrane. We also found that despite its impact on the NPC phenotype in NPC-1 mutant mice,
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overexpression of StarD4 in CHO cells does not affect accessible plasma membrane cholesterol
levels. There are still a number of possibilities for where StarD4 could be transporting
cholesterol, such as inaccessible domains of the plasma membrane, the endocytic recycling
compartment, and certain domains of the ER (Figure 26).
We were able to isolate proteins that were potentially associated with StarD5 and
narrowed these detected proteins down to a short list of candidates for a StarD5 chaperone.
Since LPDS triggers the movement of StarD5 to the plasma memrane, an ideal candidate protein
would be more strongly associated with StarD5 after exposure to LPDS. In addition, any known
chaperone protein that was associated with StarD5 would be a candidate. Unfortunately, I did
not have the time or resources to persue this project further.
StarD5 activation has the potential to act as a therapy for NPC. However, it is clear that
more research is needed in this area. This includes a more robust experiment involing the
injection a larger number of NPC-1 mutant mice with an AAV9-StarD5 virus. Alternative
behavioral tests could give more accurate information on the neurodegene ration of NPC-1
mutant mice [49]. Harvesting the cerebellum separately could help show a more complete
picture of how StarD4 and StarD5 overexpression affects the NPC phenotype in the brain
Further research is also needed to understand the function of StarD4 and StarD5. While I have
provided a list of potential StarD5 chaperones, my work here is only the first step in identifying a
StarD5 chaperone protein. The identification of a StarD5 chaperone would be a major step in
understanding the intracellular transport of cholesterol, and would also be useful in further
research on the use of StarD5 overexpression to treat NPC.
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Figure 26. A diagram describing StarD4 and StarD5 mediated cholesterol transport, and a
suggested mechanism for amelioration of the NPC phenotype.
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Conclusions

Our results shed some light on the function of StarD5. In StarD5 -/- mouse livers, several
genes have a significantly altered level of mRNA expression, likely due to the buildup of
cholesterol within the cell. We have found the strongest evidence yet that StarD5 transports
cholesterol to the plasma membrane, possibly from the endocytic recycling compartment. We
have collected a list of potential StarD5 chaperone proteins, but more research will be needed in
order to identify StarD5 chaperones.
StarD4 and StarD5 have both shown promise in ameliorating the impacts of NPC disease.
We found that overexpression of StarD4 in NPC-1 mutant mice improved motor ability and
lowered levels of intracellular cholesterol in the liver and brain. Overexpression of StarD5 in
CHO wild type and mutant cells triggered the movement of cholesterol to accessible domains of
the plasma membrane. In a preliminary experiment, we found that overexpression of StarD5
lowered mRNA expression of HMG-CoA reductase in the liver, as well as lowering levels of
cholesterol and triglycerides in the liver. However, due to the low sample size of this
experiment, a broader mouse study will be needed.
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